BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38104031)

  • 1. Prognosis and Clinicopathological Characters of Adult TFEB-Altered Renal Cell Carcinoma: A Single Center Experience of 18 Cases.
    Wu J; Cao CZ; Cui HL; Du G; Shi HZ; Liang J; Guo L; Wang YC; Zhang J; Zhou AP; Li CL; Zheng S; Shou JZ
    Clin Genitourin Cancer; 2024 Apr; 22(2):261-268.e3. PubMed ID: 38104031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A rare case of TFEB/6p21/VEGFA-amplified renal cell carcinoma diagnosed by whole-exome sequencing: clinicopathological and genetic feature report and literature review.
    Zhang R; Ding M; Zhu X; Li X; Hu Q; Tao L; Hu W; Zou H
    Diagn Pathol; 2024 May; 19(1):66. PubMed ID: 38730456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TFEB Rearranged Renal Cell Carcinoma: Pathological and Molecular Characterization of 10 Cases, with Novel Clinical Implications: A Single Center 10-Year Experience.
    Wang AX; Tian T; Liu LB; Yang F; He HY; Zhou LQ
    Biomedicines; 2023 Jan; 11(2):. PubMed ID: 36830782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and Molecular Characterization of Microphthalmia-associated Transcription Factor (MITF)-related Renal Cell Carcinoma.
    Lang M; Vocke CD; Ricketts CJ; Metwalli AR; Ball MW; Schmidt LS; Linehan WM
    Urology; 2021 Mar; 149():89-97. PubMed ID: 33242557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TFEB-amplified Renal Cell Carcinomas: An Aggressive Molecular Subset Demonstrating Variable Melanocytic Marker Expression and Morphologic Heterogeneity.
    Argani P; Reuter VE; Zhang L; Sung YS; Ning Y; Epstein JI; Netto GJ; Antonescu CR
    Am J Surg Pathol; 2016 Nov; 40(11):1484-1495. PubMed ID: 27565001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Renal cell carcinoma with t(6;11)(p21.2;q13)/MALAT1-TFEB fusion: a clinical and pathological analysis].
    Xia Q; Shi S; Shen Q; Wei X; Wang X; Ma H; Lu Z; Zhou X; Rao Q
    Zhonghua Bing Li Xue Za Zhi; 2015 Dec; 44(12):895-9. PubMed ID: 26888508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinicopathological features and prognosis of fumarate hydratase deficient renal cell carcinoma].
    Yu YF; He SM; Wu YC; Xiong SW; Shen Q; Li YY; Yang F; He Q; Li XS
    Beijing Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 53(4):640-646. PubMed ID: 34393221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathologic and Molecular Analysis of the TFEB Fusion Variant Reveals New Members of TFEB Translocation Renal Cell Carcinomas (RCCs): Expanding the Genomic Spectrum.
    Xia QY; Wang XT; Fang R; Wang Z; Zhao M; Chen H; Chen N; Teng XD; Wang X; Wei X; Ye SB; Li R; Ma HH; Lu ZF; Zhou XJ; Rao Q
    Am J Surg Pathol; 2020 Apr; 44(4):477-489. PubMed ID: 31764220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive study of nine novel cases of TFEB-amplified renal cell carcinoma: an aggressive tumour with frequent PDL1 expression.
    Kammerer-Jacquet SF; Gandon C; Dugay F; Laguerre B; Peyronnet B; Mathieu R; Verhoest G; Bensalah K; Leroy X; Aubert S; Vermaut C; Escande F; Verkarre V; Compérat E; Ambrosetti D; Pedeutour F; Belaud-Rotureau MA; Rioux-Leclercq N;
    Histopathology; 2022 Aug; 81(2):228-238. PubMed ID: 35562857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploration of clinicopathological features of rearranged renal cell carcinoma and TFE3, TFEB, and ALK staining performance in renal entities.
    Liu Y; Li X; Fan Y; Xu H; Gu Y; Dong L; Zhou L; Yang X; Wang C
    Heliyon; 2023 Apr; 9(4):e15159. PubMed ID: 37089387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinicopatholigic features of renal cell carcinoma associated with chromosome X inversion harboring gene fusions involving TFE3].
    Zhao YN; Wang XT; Xia QY; Wang GP; Sun SY; Zhao LF; Zhou XJ; Rao Q
    Zhonghua Bing Li Xue Za Zhi; 2018 Aug; 47(8):574-579. PubMed ID: 30107660
    [No Abstract]   [Full Text] [Related]  

  • 12. Eosinophilic solid and cystic renal cell carcinoma and renal cell carcinomas with TFEB alterations: a comparative study.
    Lobo J; Rechsteiner M; Helmchen BM; Rupp NJ; Weber A; Moch H
    Histopathology; 2022 Jul; 81(1):32-43. PubMed ID: 35403742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal cell carcinoma with metastases to the gallbladder: four cases from the National Cancer Institute (NCI) and review of the literature.
    Chung PH; Srinivasan R; Linehan WM; Pinto PA; Bratslavsky G
    Urol Oncol; 2012; 30(4):476-81. PubMed ID: 21277810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synchronous or metachronous presentation of pancreatic neuroendocrine tumor versus secondary lesion to pancreas in patients affected by renal cell carcinoma. Systematic review.
    Persano I; Parlagreco E; La Salvia A; Audisio M; Volante M; Buttigliero C; Scagliotti GV; Brizzi MP
    Semin Oncol; 2022 Dec; 49(6):476-481. PubMed ID: 36759234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Renal cell carcinoma in patients with end-stage renal disease: a clinicopathological analysis].
    He B; Zhang W; Liu LN; Wang H; Zou YW; Jiang YX; Yu WJ; Shi HL; Liu Y; Li YJ
    Zhonghua Bing Li Xue Za Zhi; 2019 Nov; 48(11):846-850. PubMed ID: 31775432
    [No Abstract]   [Full Text] [Related]  

  • 16. [Clinicopathological characteristics of fumarate hydratase-deficient renal cell carcinoma].
    Zhang W; Chu J; Zou YW; Jiang YX; Wei ZM; Zhong DC; Liu Y; Li YJ; Yu WJ
    Zhonghua Bing Li Xue Za Zhi; 2019 Feb; 48(2):120-126. PubMed ID: 30695864
    [No Abstract]   [Full Text] [Related]  

  • 17. Merlin immunohistochemistry is useful in diagnosis of tumours within the spectrum of biphasic hyalinizing psammomatous renal cell carcinoma.
    Collins K; Hwang M; Antic T; Paintal A; Argani P; Matoso A; Gopinath A; Baskovich B; Mehra R; Williamson SR; Idrees MT; Barletta JA; Anderson WJ; Hirsch MS; Hornick JL; Acosta AM
    Histopathology; 2022 Nov; 81(5):577-586. PubMed ID: 35971742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expanding the morphologic spectrum of chromophobe renal cell carcinoma: A study of 8 cases with papillary architecture.
    Michalova K; Tretiakova M; Pivovarcikova K; Alaghehbandan R; Perez Montiel D; Ulamec M; Osunkoya A; Trpkov K; Yuan G; Grossmann P; Sperga M; Ferak I; Rogala J; Mareckova J; Pitra T; Kolar J; Michal M; Hes O
    Ann Diagn Pathol; 2020 Feb; 44():151448. PubMed ID: 31918172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma.
    Beck SD; Patel MI; Snyder ME; Kattan MW; Motzer RJ; Reuter VE; Russo P
    Ann Surg Oncol; 2004 Jan; 11(1):71-7. PubMed ID: 14699037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diverse fusion patterns and heterogeneous clinicopathologic features of renal cell carcinoma with t(6;11) translocation.
    Inamura K; Fujiwara M; Togashi Y; Nomura K; Mukai H; Fujii Y; Yamamoto S; Yonese J; Fukui I; Ishikawa Y
    Am J Surg Pathol; 2012 Jan; 36(1):35-42. PubMed ID: 22173116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.